PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells industry that proposal on trials also can’t use SPA-like process.
You may also be interested in...
FDA May Not Implement User Fee Workload Adjuster In PDUFA VI
Three-to-five year timeline needed to develop algorithms does not engender confidence that new version of formula, which historically pushed user fee rates higher, will be ready before PDUFA VII begins.
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.
FDA Prescription Drug User Fee Program Will Get OIG Appraisal
In addition to user fees, upcoming FDA reviews will also focus on oversight of post-marketing requirements and information exchange in the drug supply chain.